Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of insulin degludec/insulin aspart versus insulin glargine in type 2 diabetes
KCT0004597Phase 4Active, not recruiting
- Sponsor
- Korean Diabetes Association
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin degludec, insulin aspart, insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Korean Diabetes Association. Started Oct 2020; status: active, not recruiting.
02
Drugs
insulin degludecinsulin aspartinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0004597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004597.